Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Pembrolizumab, Guadecitabine, and Mocetinostat in Treating Patients with Stage IIIb-IV Non-small Cell Lung Cancer

Trial Status: closed to accrual

This phase I/Ib trial studies the side effects and best dose of guadecitabine and mocetinostat and how well they work when given together with pembrolizumab in treating patients with stage IIIb-IV non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as guadecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Mocetinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab, guadecitabine, and mocetinostat together may work in treating patients with non-small cell lung cancer.